List of Antiviral Therapies Companies in Belgium - 2

Search through the full list with powerful filtering options

Company	About
Complix Diepenbeek, Belgium	A biotech company dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies are robust and versatile protein scaffolds, unrelated to immunoglobulins, and inspired by naturally occurring motives. Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a broad range of intracellular disease related targets that are considered “intractable” by currently available drug formats, such as antibodies and small molecules.
Vésale Bioscience Mont-St-Guibert, Walloon Region	Stem from our advanced R&D on bacteriophages, our Mission is to develop robust modern solutions to fight drug-resistant infections. Antimicrobial resistance (AMR) is a substantial public health issue. From 700 000/y deaths today, the AMR burden is expected to reach ten million/y deaths by 2050, more than cancer. Our approach is to work on personalized, selective, and specific phage therapies against those multi-resistant bacterial infections.

Company

About

Complix

Diepenbeek, Belgium

A biotech company dedicated to the discovery and development of protein therapeutics using its proprietary alphabody™ technology. Alphabodies are robust and versatile protein scaffolds, unrelated to immunoglobulins, and inspired by naturally occurring motives. Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a broad range of intracellular disease related targets that are considered “intractable” by currently available drug formats, such as antibodies and small molecules.

Vésale Bioscience

Mont-St-Guibert, Walloon Region

Stem from our advanced R&D on bacteriophages, our Mission is to develop robust modern solutions to fight drug-resistant infections. Antimicrobial resistance (AMR) is a substantial public health issue. From 700 000/y deaths today, the AMR burden is expected to reach ten million/y deaths by 2050, more than cancer. Our approach is to work on personalized, selective, and specific phage therapies against those multi-resistant bacterial infections.